Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Arbutus Biopharma Corp ABUS

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company. The Company is leveraging its virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV) infection. Its HBV product pipeline includes Imdusiran and AB-101. Imdusiran is its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic product candidate. AB-101 is an oral PD-L1 inhibitor that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for.


NDAQ:ABUS - Post by User

Bullboard Posts
Post by sometoaston May 16, 2007 11:39am
331 Views
Post# 12789568

TKM Market Cap

TKM Market CapTekmira's market cap is now about equal to their cash on hand (i.e., $30 million). It would seem that the street is giving little value to their internal work or their projects/relationships with ALNY or Hana. Which is too bad because I still think RNAi is one of the more exciting fields (but yes still much proof is required). Also, Inex seems to have shown that their liposomes do actually help deliver drups better in other indications such that if RNAi works, it could really be a pivotal tool. From my recent non-response from numerous inquiries, I am not sure that TKM's management is overly concerned with shareholders (I think they feel we are a necessary evil but do not need to respond to our concerns). But this does not justify the poor market cap. I am still hopeful in their technology but I am beginning to wonder if some bad news may be leaking out somewhere...
Bullboard Posts